Taku Tadenuma

Dr. Taku Tadenuma


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2016 in Skeletal Radiology
Verified
Journal Article
Closed access
PDF file
TTTaku Tadenuma
Taku Tadenuma
YUYuji Uchio
Yuji Uchio
NKNobuyuki Kumahashi
Nobuyuki Kumahashi
EFEiji Fukuba
Eiji Fukuba
HKHajime Kitagaki
Hajime Kitagaki
MOMitsuo Ochi
Mitsuo Ochi

30 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TTTaku Tadenuma
Taku Tadenuma
Yuji UchioYuji Uchio
Yuji Uchio
TWTakuya Wakatsuki
Takuya Wakatsuki
HTHiroshi Takuwa
Hiroshi Takuwa
SKSuguru Kuwata
Suguru Kuwata
Objectives: To evaluate the effectiveness and durability of matrix-associated autologous chondrocyte implantation with periosteal flap (pMACI) in treating knee cartilage defects using clinical scores and MRI evaluations. Methods: Data were collected from 37 knees of 17 patients, with a mean follow-up of 5 years (range: 0.1–20 years). Clinical outcomes were assessed using the Lysholm Knee Scoring Scale (LKS) and Knee Injury and Osteoarthritis Outcome Score (KOOS). Tissue quality was quantitatively evaluated using MRI T1ρ and T2 mapping (biochemical) and MR observation of cartilage repair tissue: MOCART 2.0 (morphological). A linear mixed model was used to identify factors affecting outcomes, including etiology (trauma, OCD, OA), graft site, and defect size. Results: At the 20-year follow-up, clinical scores remained significantly improved from baseline (mean LKS: 55.6 to 86.5; KOOS: 37.8 to 70.8). The biochemical MRI parameters (T1ρ and T2 values) stabilized at levels comparable to native cartilage across all etiologies and sites (p = 0.326 and 0.412, respectively), indicating stable long-term tissue quality. In contrast, the MOCART 2.0 scores significantly declined over time (annual rate: −1.14 points; p < 0.001). Etiology was a significant factor; the OA group showed significantly lower clinical and MOCART scores compared to the trauma/OCD groups (p < 0.05). However, no significant differences were found in LKS and KOOS based on graft site (p = 0.489) or defect size (p > 0.05). Conclusions: pMACI may be a highly durable treatment capable of maintaining biological tissue quality and providing clinical benefits for two decades. The observed morphological deterioration after 20 years likely reflects joint-wide aging—especially in OA cases—rather than graft failure, highlighting the importance of long-term MRI monitoring.